Clinical trials · New York
Focal Segmental Glomerulosclerosis clinical trials in New York
We’re tracking 10 recruiting focal segmental glomerulosclerosis studies with a site in New York — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07220083RecruitingPhase 3
A study of BI 764198 for people with FSGS kidney disease
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
Clifton Park, New YorkAges 12 years+ - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
New York, New YorkAges 16–75 - NCT02235857Recruiting
Device treatment study for children with focal segmental kidney scarring
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
New York, New YorkAges Up to 21 years - NCT04065438Recruiting
Study of a blood-filter treatment for FSGS not responding to meds
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
New York, New YorkAges Up to 75 years - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
New Hyde Park, New YorkAges 1–80 - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
New York, New YorkAges 1–17 - NCT05583942Recruiting
Nerve stimulation trial for children with steroid-resistant kidney syndrome
This pilot study tests a device that stimulates nerves in the ear to help children with steroid-resistant nephrotic syndrome. It may improve urine protein and kidney-related outcomes for kids whose standard steroid treatment does not work.
New Hyde Park, New YorkAges 3–17 - NCT05588063Recruiting
Device-based nerve stimulation for relapse-preventing kidney disease in kids
This trial tests whether a small non-surgical device can help keep children with steroid-sensitive nephrotic syndrome in remission. If it works, it could lower the chance of relapse (kidney flare-ups) and help maintain kidney health.
New Hyde Park, New YorkAges 3–17 - NCT06090227RecruitingPhase 1/Phase 2
Metformin for FSGS: A phase 1/2 trial
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
New York, New YorkAges 18–80 - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
New York, New YorkAges Up to 80 years
Focal Segmental Glomerulosclerosis trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting focal segmental glomerulosclerosis studies listed above.
- The Steven and Alexandra Cohen Children's Medical Center of New York · 5 studies
- Columbia University Irving Medical Center · 2 studies
- Weill Cornell Medicine · 2 studies
- Bellevue Hospital Center
- Fink Children's Ambulatory Care Center
- Investigational Site 003
- Montefiore Medical Center
- Mount Sinai Hospital
What taking part in a focal segmental glomerulosclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Focal Segmental Glomerulosclerosis trials in other states
Common questions
- Are there focal segmental glomerulosclerosis clinical trials in New York?
- Yes. We're currently tracking 10 recruiting focal segmental glomerulosclerosis studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a focal segmental glomerulosclerosis study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a focal segmental glomerulosclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New focal segmental glomerulosclerosis studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.